Isarna Therapeutics Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Isarna Therapeutics General Information
Description
Developer of antisense therapies designed to target beta-growth factor signaling for fibrosis and other indications. The company is developing a portfolio of antisense therapies targeting beta-growth factor signaling, with a lead compound in Phase 2a clinical development in ophthalmology and additional antisense compounds addressing three beta-growth factor isoforms for fibrotic liver disease, such as NASH and various forms of cancer, enabling clinical researchers and healthcare providers to pursue safer and more effective treatment options across multiple indications.
Contact Information
Website
www.isarna-therapeutics.comCorporate Office
- Bussardstrasse 5 / 2
- 82166 Gräfelfing
- Germany
Corporate Office
- Bussardstrasse 5 / 2
- 82166 Gräfelfing
- Germany
Isarna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 01-Mar-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Secondary Transaction - Private | 01-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 28-May-2014 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 06-Jul-2011 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 15-Mar-2010 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | 08-Nov-2007 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC | 30-Nov-2005 | $18M | $37.8M | Completed | Clinical Trials - Phase 1 | |
| 1. Later Stage VC | 29-Apr-2004 | $19.8M | $19.8M | Completed | Clinical Trials - Phase 1 |
Isarna Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Isarna Therapeutics Patents
Isarna Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026120154-A1 | Oligonucleotide for use in treating retinal pathologies | Pending | 06-Dec-2024 | ||
| EP-3538655-A1 | Tgf-beta oligonucleotide for use in treatment of ophthalmic diseases | Pending | 11-Nov-2016 | ||
| US-11207341-B2 | Tgf-beta oligonucleotide for use in treatment of ophthalmic diseases | Active | 11-Nov-2016 | ||
| US-20190262384-A1 | Tgf-beta oligonucleotide for use in treatment of ophthalmic diseases | Active | 11-Nov-2016 | ||
| WO-2018087359-A1 | Tgf-beta oligonucleotide for use in treatment of ophthalmic diseases | Inactive | 11-Nov-2016 | C12N15/1136 |
Isarna Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Isarna Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Global Chance Fund | Venture Capital | Minority |
Isarna Therapeutics FAQs
-
When was Isarna Therapeutics founded?
Isarna Therapeutics was founded in 1998.
-
Where is Isarna Therapeutics headquartered?
Isarna Therapeutics is headquartered in Gräfelfing, Germany.
-
What is the size of Isarna Therapeutics?
Isarna Therapeutics has 7 total employees.
-
What industry is Isarna Therapeutics in?
Isarna Therapeutics’s primary industry is Drug Discovery.
-
Is Isarna Therapeutics a private or public company?
Isarna Therapeutics is a Private company.
-
What is Isarna Therapeutics’s current revenue?
The current revenue for Isarna Therapeutics is .
-
How much funding has Isarna Therapeutics raised over time?
Isarna Therapeutics has raised $131M.
-
Who are Isarna Therapeutics’s investors?
Global Chance Fund has invested in Isarna Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
